{"id":"everolimus-afinitor","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Stomatitis/mouth ulcers"},{"rate":"30-40","effect":"Rash"},{"rate":"25-35","effect":"Diarrhea"},{"rate":"25-30","effect":"Fatigue"},{"rate":"20-30","effect":"Nausea"},{"rate":"15-25","effect":"Anemia"},{"rate":"10-20","effect":"Thrombocytopenia"},{"rate":"15-25","effect":"Hyperlipidemia"},{"rate":"10-20","effect":"Hyperglycemia"},{"rate":"1-5","effect":"Pneumonitis"}]},"_chembl":{"chemblId":"CHEMBL1908360","moleculeType":"Small molecule","molecularWeight":"958.24"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Everolimus is an mTOR inhibitor that suppresses the mTORC1 signaling pathway, which regulates protein synthesis, cell cycle progression, and angiogenesis. By blocking mTOR activity, it reduces tumor cell proliferation and can induce cell cycle arrest. This mechanism is particularly effective in cancers with dysregulated mTOR signaling and in preventing organ rejection.","oneSentence":"Everolimus inhibits mTOR (mammalian target of rapamycin), a key protein kinase that controls cell growth and proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:49.472Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced renal cell carcinoma"},{"name":"Breast cancer (hormone receptor-positive, HER2-negative)"},{"name":"Pancreatic neuroendocrine tumors"},{"name":"Subependymal giant cell astrocytoma (SEGA)"},{"name":"Organ transplant rejection prophylaxis"}]},"trialDetails":[{"nctId":"NCT04802759","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-06-22","conditions":"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer","enrollment":316},{"nctId":"NCT02143726","phase":"PHASE2","title":"Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2014-10-09","conditions":"Refractory Hurthle Cell Thyroid Cancer","enrollment":35},{"nctId":"NCT02081755","phase":"PHASE4","title":"Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Baylor Research Institute","startDate":"2014-03","conditions":"Carcinoma, Hepatocellular","enrollment":336},{"nctId":"NCT06680921","phase":"PHASE3","title":"A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)","status":"RECRUITING","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2024-11-14","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":460},{"nctId":"NCT03049189","phase":"PHASE3","title":"Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"ITM Solucin GmbH","startDate":"2017-02-02","conditions":"Neuroendocrine Tumors","enrollment":309},{"nctId":"NCT03324373","phase":"PHASE1","title":"Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)","status":"COMPLETED","sponsor":"Yousef Zakharia","startDate":"2019-03-20","conditions":"Renal Cell Carcinoma","enrollment":11},{"nctId":"NCT06789900","phase":"PHASE2","title":"Everolimus and/or Exercise to Prevent Bone Loss in Postmenopausal Women","status":"RECRUITING","sponsor":"Odense University Hospital","startDate":"2024-10-14","conditions":"Postmenopausal Women","enrollment":136},{"nctId":"NCT03577431","phase":"PHASE1, PHASE2","title":"Liver Transplantation With Tregs at MGH","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-03-29","conditions":"Liver Transplant","enrollment":9},{"nctId":"NCT02155920","phase":"PHASE2","title":"Everolimus for Children With Recurrent or Progressive Ependymoma","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2015-02","conditions":"Recurrent Childhood Ependymoma","enrollment":11},{"nctId":"NCT03654040","phase":"PHASE1, PHASE2","title":"Liver Transplantation With Tregs at UCSF","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-22","conditions":"Liver Transplant","enrollment":42},{"nctId":"NCT03525834","phase":"PHASE4","title":"Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-09","conditions":"Renal Angiomyolipoma","enrollment":40},{"nctId":"NCT02451696","phase":"PHASE2","title":"A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2014-01","conditions":"Epilepsy, Tuberous Sclerosis Complex, Focal Cortical Dysplasia","enrollment":15},{"nctId":"NCT01784861","phase":"PHASE1, PHASE2","title":"VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2013-05-03","conditions":"Adenocarcinoma, Pancreatic Neoplasms","enrollment":23},{"nctId":"NCT01088048","phase":"PHASE1","title":"Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-03-25","conditions":"Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma","enrollment":241},{"nctId":"NCT01482156","phase":"PHASE1","title":"Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-01","conditions":"Advanced Solid Tumors, Metastatic Breast Cancer, Metastatic Renal Cell Carcinoma","enrollment":46},{"nctId":"NCT00968591","phase":"PHASE1","title":"Pharmacokinetics of Everolimus in Subjects With Hepatic Insufficiency","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-11","conditions":"Hepatic Insufficiency","enrollment":34},{"nctId":"NCT01051570","phase":"PHASE2","title":"Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2010-02","conditions":"Prostate Cancer","enrollment":26},{"nctId":"NCT02113800","phase":"PHASE2","title":"Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2015-08","conditions":"Poorly Differentiated Malignant Neuroendocrine Carcinoma, Neuroendocrine Carcinoma, Grade 3, Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3","enrollment":40},{"nctId":"NCT02201212","phase":"PHASE2","title":"Everolimus for Cancer With TSC1 or TSC2 Mutation","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-09","conditions":"TSC1, TSC2, Tuberous Sclerosis Complex","enrollment":30},{"nctId":"NCT01596140","phase":"PHASE1","title":"Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-12-18","conditions":"Advanced Cancer, Solid Tumor","enrollment":27},{"nctId":"NCT00976755","phase":"PHASE2","title":"Everolimus as First-Line Therapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2009-09-14","conditions":"Prostate Cancer","enrollment":37},{"nctId":"NCT02985125","phase":"PHASE1, PHASE2","title":"LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Georgetown University","startDate":"2017-05-04","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":44},{"nctId":"NCT01567488","phase":"PHASE2","title":"Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET","status":"COMPLETED","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2011-06-08","conditions":"Gastrointestinal Neoplasms","enrollment":43},{"nctId":"NCT02248571","phase":"PHASE4","title":"Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab","status":"COMPLETED","sponsor":"iOMEDICO AG","startDate":"2014-08","conditions":"Breast Cancer Recurrent, HER2/Neu-negative Carcinoma of Breast, Hormone Receptor Positive Malignant Neoplasm of Breast","enrollment":85},{"nctId":"NCT01419639","phase":"PHASE2","title":"Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2011-10","conditions":"Neurofibromatosis Type II","enrollment":10},{"nctId":"NCT01379521","phase":"PHASE2","title":"Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-06","conditions":"Hepatocellular Carcinoma","enrollment":65},{"nctId":"NCT02013089","phase":"NA","title":"A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2013-12","conditions":"Gastrointestinal Cancers","enrollment":50},{"nctId":"NCT01801137","phase":"PHASE2","title":"The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium","status":"COMPLETED","sponsor":"Hopital Foch","startDate":"2011-06","conditions":"Urothelial Cancer","enrollment":54},{"nctId":"NCT01118065","phase":"PHASE2","title":"Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2010-05","conditions":"Head and Neck Cancer","enrollment":42},{"nctId":"NCT01175096","phase":"PHASE1, PHASE2","title":"Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2010-07","conditions":"Neuroendocrine Tumors, Carcinoid Tumor","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Football fitness session"],"phase":"phase_3","status":"active","brandName":"Everolimus (Afinitor®)","genericName":"Everolimus (Afinitor®)","companyName":"Odense University Hospital","companyId":"odense-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Everolimus (Afinitor) is a small molecule inhibitor of the FK506-binding protein 1A, which is involved in the mTOR pathway. It has been studied in various clinical trials for conditions such as postmenopausal bone loss, head and neck cancer, and breast cancer, among others.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}